North Mississippi Primary Health Care, Inc. | |
15921 Boundary Dr Ashland MS 38603-7740 | |
(662) 224-8951 | |
(662) 224-6801 |
Full Name | North Mississippi Primary Health Care, Inc. |
---|---|
Speciality | Dentist - General Practice |
Location | 15921 Boundary Dr, Ashland, Mississippi |
Authorized Official Name and Position | Tammy G Chapman (CFO) |
Authorized Official Contact | 6625023137 |
Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
Mailing Address | Practice Location Address |
---|---|
North Mississippi Primary Health Care, Inc. Po Box 92 Ashland MS 38603-0092 Ph: (662) 502-3137 | North Mississippi Primary Health Care, Inc. 15921 Boundary Dr Ashland MS 38603-7740 Ph: (662) 224-8951 |
NPI Number | 1447993456 |
---|---|
Provider Enumeration Date | 04/18/2022 |
Last Update Date | 04/18/2022 |
Identifier | Type | State | Issuer |
---|---|---|---|
1447993456 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
1223G0001X | Dentist - General Practice | (* (Not Available)) | Primary |
News Archive
Scientists have found that sperm from diabetic men have greater levels of DNA damage than sperm from men who do not have the disease.
In a new statewide poll released by PANPHA, which conducted a head-to-head comparison of the state's most important issues, Pennsylvanians believe senior care services should be one of the top funding priorities, placing it ahead of roads and bridges, environmental programs and the arts.
The new database is now available to marketing, business development, competitor intelligence, KOL, medical affairs and related departments in the life sciences sector.
An interview with Jean Fallacara, CEO, discussing how Z-SC1 help to ensure safe sample storage at ultra-low temperatures, conducted by James Ives, MPsych
Receptos, Inc., a privately held biopharmaceutical company, announced the closing of a two-tranche $25 million Series A financing. The company is focused on identifying and developing best- and first-in-class GPCR therapeutic candidates through information-driven drug discovery, including GPCR structure. Investors include ARCH Venture Partners, Flagship Ventures, Lilly Ventures and Venrock.
› Verified 6 days ago